Medifast Logo
US58470H1014
889384
MED

Medifast

Cargando cotizaciones...

Previsión

El precio objetivo medio de los analistas es de 10,93 € (-2,41 %). La mediana es de 10,93 € (-2,41 %).

Comprar
  4
Mantener
  6
Vender
  2

Debates en la comunidad

Todavía no hay ninguna discusión sobre este activo.

Iniciar debate

  • Medifast beats Q2 expectations and stock rises sharply after-hours

    Medifast reported a narrower Q2 loss of $0.28 per share and revenue of $76.4 million, both slightly better than analysts had expected. Despite a 27.6% decline in revenue and a steep drop in active coaches, productivity per coach rose significantly. The launch of the Trilivy brand and cost-cutting measures are intended to support a repositioning toward metabolic health and put the company on track to return to profitability in Q4 2026. The stock gained about 14% after-hours while Medifast left its full-year guidance unchanged. » Más en de.investing.com


  • Medifast replaces OPTAVIA with Trilivy and shifts focus to metabolic health

    Medifast is introducing the Trilivy system to replace the OPTAVIA brand and is offering reformulated meal-replacement products called Trilivy Reset Fueling that use MetaVantage technology. The rebranding signals a strategic shift from pure weight loss toward addressing metabolic health with a three-phase program (Reset, Refine, Renew) and a network of independent coaches. The company notes a 36% decline in revenue but a 70% gross profit margin; the new products are slated to launch in August and are intended to positively impact visceral fat as well as insulin and fat metabolism. » Más en de.investing.com


  • Medifast appoints Nicholas Johnson as CEO effective June 1

    Medifast’s board has appointed Nicholas Johnson as chief executive officer effective June 1, 2026; Dan Chard remains chairman of the board. The appointment follows a succession plan announced in January; Johnson most recently served as president and has held various leadership roles since 2018. Medifast faces strong headwinds: revenue fell 36% over the past twelve months to $346.1 million and the company posted a loss of $1.82 per share, with analysts not expecting a return to profitability this year. Despite the troubles, gross profit margin remains high at 70%, the stock is up 17.9% year-to-date and trades around $13.08 with a market capitalization of about $132.6 million. » Más en de.investing.com


  • Medifast misses revenue forecast despite better quarterly EPS, shares fall

    Medifast reported Q1 2026 EPS of -$0.19, beating the estimate of -$0.36, while revenue of $76 million missed expectations of $85.5 million. The stock fell about 2.6% premarket and is approaching its 52-week low. The company recorded its first sequential revenue growth in three years and improved coach productivity, but still expects declining revenues and forecasted further EPS losses. Management is focusing on operational efficiency and a metabolic system planned for July 2026, but sees risks from GLP-1 drugs and continued revenue declines. » Más en de.investing.com


  • Medifast pivots strategy toward metabolic health after quarterly loss

    Medifast reported a loss per share of $1.65 for Q4 2025 on revenue of $75 million, with revenue slightly above expectations but profitability dropping sharply. Gross margin fell by 470 basis points, active coaches declined while revenue per active coach rose 6%. For 2026 the company forecasts revenue of $270–300 million and continued losses, but expects a profit recovery from Q4 2026 driven by new products, operational savings of over $30 million, a strong liquidity position of $167 million and debt-free status. » Más en de.investing.com

En 2023, Medifast ya ha pagado 6,08 € en dividendos. El último pago fue en noviembre de 2023.

Datos financieros de la empresa

En el último trimestre, Medifast tuvo unos ingresos de 63,61 M € y un beneficio neto de -15,46 M €
(EUR) septiembre de 2026
YoY
Ingresos 63,61 M 16,51 %
Beneficio bruto 44,18 M 16,59 %
Beneficio neto -15,46 M 702,40 %
EBITDA -15,75 M 2424,27 %

Datos fundamentales

Métrica Valor
Capitalización bursátil
132,15 M €
Número de acciones
11,18 M
Máximo/mínimo de 52 semanas
12,42 € - 8,40 €
Dividendos No
Beta
0,69
Ratio P/E
-3,51
Ratio PEG
0,00
Ratio P/B
0,80
Ratio P/S
0,48

Perfil de la empresa

Medifast, Inc., a través de sus filiales, fabrica y distribuye productos para la pérdida de peso, el control del peso, productos para una vida saludable y otros productos de consumo de salud y nutrición en Estados Unidos y en la región Asia-Pacífico. La compañía ofrece barritas, bocados, pretzels, puffs, cereal crujiente, bebidas, opciones sustanciosas, avena, tortitas, pudin, helados suaves, batidos, smoothies, bizcochos blandos y sopas bajo las marcas OPTAVIA, Optimal Health by Take Shape for Life y Flavors of Home. Comercializa sus productos mediante transacciones en punto de venta a través de plataformas de comercio electrónico. La empresa fue fundada en 1980 y tiene su sede en Baltimore, Maryland.

Nombre
Medifast
CEO
Nicholas Johnson
Sede Baltimore, md
Estados Unidos
Sitio web
Sector
Consumo básico
Industria
Productos de cuidado personal
Salida a bolsa
30/12/1993
Empleados 380

Símbolos bursátiles

Bolsa Símbolo
NYSE
MED
London Stock Exchange
0K05.L
Frankfurt
MDF.F
Düsseldorf
MDF.DU
London
0K05.L
SIX
MDF.SW
München
MDF.MU
🍪

Parqet  usa cookies. Más información